2. Disease Areas
  3. Neurological, Eye or Ear Disease
  4. Nervous System Injury

Nervous System Injury

Injuries to the nervous system, including peripheral nerve injury (PNI) and central nervous system (CNS) injury, result from explosive blasts and can cause immediate or delayed mortality. Clinical manifestations often involve headache, vertigo, seizures, and altered mental status, with posttraumatic stress disorder commonly occurring in affected individuals.

 

Nervous System Injury (3):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N0385
    Gomisin J 66280-25-9 99.97%
    Gomisin J is a Schisandra chinensis-derived lignan that can inhibit multiple targets such as eNOS, AMPK (LKB1, CaMKIIβ), fetuin-A, NF-κB, Nrf2/HO-1, and can pass through the blood-brain barrier. Gomisin J increases NO bioavailability by activating eNOS, regulates lipid metabolism by activating the AMPK pathway, inhibits fetuin-A and NF-κB to exert anti-inflammatory effects, and activates Nrf2/HO-1 to enhance antioxidant capacity. Gomisin J has the activities of anti-hypertension, regulating liver lipid metabolism, and reducing cerebral ischemia-reperfusion injury, and can be used for research on hypertension, non-alcoholic fatty liver disease, cerebral ischemia-reperfusion injury, etc.
    Gomisin J
  • HY-106262
    Delcasertib 949100-39-4 98.21%
    Delcasertib (KAI-9803) is a potent and selective δ-protein kinase C (δPKC) inhibitor. Delcasertib (KAI-9803) could ameliorate injury associated with ischemia and reperfusion in animal models of acute myocardial infarction (MI).
    Delcasertib
  • HY-P99886
    Pexelizumab 219685-93-5
    Pexelizumab (h5G1. 1-SC) is a humanized scFv monoclonal antibody directed against the C5 complement component. Pexelizumab inhibits apoptosis and leukocyte infiltration. Pexelizumab can be used for the research of cerebral IR injury and myocardial infarction.
    Pexelizumab